Compare Stocks: SLRX, NEUP, AKTX, and DYAI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$8.72 -1.4%	$9.06	$3.02 ▼ $44.20	$17.21M	1.43	72,735 shs	15,258 shs
DYAI Dyadic International	$0.46 +6.1%	$0.67	$0.34 ▼ $1.60	$17.21M	0.96	192,908 shs	142,057 shs
NEUP Neuphoria Therapeutics	$3.47 -1.1%	$3.78	$3.19 ▼ $21.40	$18.99M	0.75	15,629 shs	12,581 shs
SLRX Salarius Pharmaceuticals	$0.84 +28.5%	$0.78	$0.51 ▼ $34.65	$4.90M	0.33	808,890 shs	5.99 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	-1.36%	-10.66%	-14.09%	-16.23%	-77.76%
DYAI Dyadic International	+6.10%	+9.57%	-13.05%	-51.54%	-64.94%
NEUP Neuphoria Therapeutics	-1.14%	-4.67%	-7.47%	+2.66%	-74.95%
SLRX Salarius Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-78.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$8.72 -1.4%	$9.06	$3.02 ▼ $44.20	$17.21M	1.43	72,735 shs	15,258 shs
DYAI Dyadic International	$0.46 +6.1%	$0.67	$0.34 ▼ $1.60	$17.21M	0.96	192,908 shs	142,057 shs
NEUP Neuphoria Therapeutics	$3.47 -1.1%	$3.78	$3.19 ▼ $21.40	$18.99M	0.75	15,629 shs	12,581 shs
SLRX Salarius Pharmaceuticals	$0.84 +28.5%	$0.78	$0.51 ▼ $34.65	$4.90M	0.33	808,890 shs	5.99 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	-1.36%	-10.66%	-14.09%	-16.23%	-77.76%
DYAI Dyadic International	+6.10%	+9.57%	-13.05%	-51.54%	-64.94%
NEUP Neuphoria Therapeutics	-1.14%	-4.67%	-7.47%	+2.66%	-74.95%
SLRX Salarius Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-78.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.80	Moderate Buy	$32.33	270.80% Upside
DYAI Dyadic International	2.00	Hold	$3.00	558.18% Upside
NEUP Neuphoria Therapeutics	1.67	Reduce	$7.00	101.73% Upside
SLRX Salarius Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SLRX, NEUP, AKTX, and DYAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	AKTX Akari Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/27/2026	NEUP Neuphoria Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/12/2026	DYAI Dyadic International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/6/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
DYAI Dyadic International	$3.09M	5.91	N/A	N/A	$0.03 per share	15.19
NEUP Neuphoria Therapeutics	$1.17M	16.05	N/A	N/A	$4.55 per share	0.76
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	$14.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	12/4/2026 (Estimated)
DYAI Dyadic International	-$7.36M	-$0.23	N/A	N/A	N/A	-201.43%	-2,920.31%	-84.77%	11/11/2026 (Estimated)
NEUP Neuphoria Therapeutics	-$13.45M	-$6.22	N/A	N/A	N/A	N/A	-38.31%	-28.92%	10/5/2026 (Estimated)
SLRX Salarius Pharmaceuticals	-$5.58M	-$33.89	N/A	N/A	N/A	N/A	-401.05%	-155.77%	N/A

Latest SLRX, NEUP, AKTX, and DYAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
10/5/2026	Q4 2026	NEUP Neuphoria Therapeutics	-$1.58	N/A	N/A	N/A	N/A	N/A
8/12/2026	Q2 2026	DYAI Dyadic International	-$0.0350	-$0.06	-$0.0250	-$0.06	$1.03 million	$0.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.60	0.60
DYAI Dyadic International	N/A	1.65	1.65
NEUP Neuphoria Therapeutics	N/A	27.83	27.83
SLRX Salarius Pharmaceuticals	N/A	3.28	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
DYAI Dyadic International	27.95%
NEUP Neuphoria Therapeutics	15.90%
SLRX Salarius Pharmaceuticals	11.88%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
DYAI Dyadic International	20.90%
NEUP Neuphoria Therapeutics	1.55%
SLRX Salarius Pharmaceuticals	0.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	5	1.95 million	1.32 million	Not Optionable
DYAI Dyadic International	5	40.06 million	31.69 million	Optionable
NEUP Neuphoria Therapeutics	8	5.41 million	5.33 million	N/A
SLRX Salarius Pharmaceuticals	20	5.86 million	5.84 million	Not Optionable

SLRX, NEUP, AKTX, and DYAI Headlines

Recent News About These Companies

Salarius Pharmaceuticals, Inc. Common Stock (SLRX) Insider Activity

April 3, 2026 | nasdaq.com

Salarius to Change Name

January 7, 2026 | baystreet.ca

Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics

January 7, 2026 | in.investing.com

Salarius shares jump after rebranding announcement to Decoy Therapeutics

January 7, 2026 | msn.com

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

January 7, 2026 | globenewswire.com

Salarius shareholders back directors, executive pay and auditor

January 2, 2026 | msn.com

Salarius shareholders back directors, executive pay and auditor

January 2, 2026 | msn.com

Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency

January 2, 2026 | msn.com

Salarius Pharmaceuticals appeals Nasdaq delisting after bid deficiency

January 2, 2026 | msn.com

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

December 19, 2025 | globenewswire.com

Salarius announces planned corporate name change to Decoy Therapeutics

December 18, 2025 | msn.com

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide ...

December 18, 2025 | finance.yahoo.com

Salarius Pharmaceuticals, Inc. Transforms into Decoy Therapeutics, Inc. with NASDAQ Ticker Change to DCOY Effective January 2026

December 18, 2025 | quiverquant.comQ

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

December 18, 2025 | globenewswire.com

Salarius Pharmaceuticals, Texas Biomed collaborate on Avian Flu study

December 1, 2025 | msn.com

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

December 1, 2025 | globenewswire.com

Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Purchases $16,000.00 in Stock

November 21, 2025 | insidertrades.com

Salarius Pharmaceuticals affirms shares continue to trade on the Nasdaq

November 20, 2025 | msn.com

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the ...

November 19, 2025 | markets.businessinsider.com

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

November 19, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRX, NEUP, AKTX, and DYAI Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$8.72 -0.12 (-1.36%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$8.76 +0.04 (+0.46%)

As of 10/2/2026 07:30 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Dyadic International NASDAQ:DYAI

$0.46 +0.03 (+6.10%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.92%)

As of 10/2/2026 07:13 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Neuphoria Therapeutics NASDAQ:NEUP

$3.47 -0.04 (-1.14%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$3.46 -0.01 (-0.14%)

As of 10/2/2026 07:30 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Salarius Pharmaceuticals NASDAQ:SLRX

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLRX, NEUP, AKTX, and DYAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLRX, NEUP, AKTX, and DYAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLRX, NEUP, AKTX, and DYAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRX, NEUP, AKTX, and DYAI Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Dyadic International NASDAQ:DYAI

Neuphoria Therapeutics NASDAQ:NEUP

Salarius Pharmaceuticals NASDAQ:SLRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLRX, NEUP, AKTX, and DYAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLRX, NEUP, AKTX, and DYAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLRX, NEUP, AKTX, and DYAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRX, NEUP, AKTX, and DYAI Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Dyadic International NASDAQ:DYAI

Neuphoria Therapeutics NASDAQ:NEUP

Salarius Pharmaceuticals NASDAQ:SLRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools